Heather Bartels, MD
Ophthalmology · Peterborough, NHNPI 1386098648
Payments from drug & device makers
What this record shows
This record is dominated by other: $5,589 of the $7,537 with a category attached, or 74.2%. Carl Zeiss Meditec Digital Innovations LLC accounts for 74.2% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2024 at $6,245 and has fallen 93.1% since, to $430 in 2025. Among ophthalmology clinicians in NH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 62 payments — averaging $121.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec Digital Innovations LLC$6K
- Alcon$529
- AbbVie$483
- Bausch & Lomb Americas Inc.$219
- Glaukos Corporation$152
- Dompe US, Inc.$120
- plus $446 from 14 others
What the payments were for
- Food & beverage$1,94826%
- Other$5,58974%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec Digital Innovations LLC | 1 | $5,589 |
| Alcon | 17 | $529 |
| AbbVie(2 entities) | 19 | $483 |
| Bausch & Lomb Americas Inc. | 4 | $219 |
| Glaukos Corporation | 3 | $152 |
| Dompe US, Inc. | 1 | $120 |
| Ivantis, Inc | 1 | $107 |
| Regeneron Healthcare Solutions, Inc. | 1 | $39 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $37 |
| Sun Pharmaceutical Industries Inc. | 2 | $36 |
| Astellas Pharma US Inc | 1 | $33 |
| Biotissue Holdings Inc. | 2 | $31 |
| Mallinckrodt Hospital Products Inc. | 1 | $27 |
| Rayner Intraocular Lenses Limited | 1 | $26 |
| Johnson & Johnson Vision Care, Inc. | 1 | $24 |
| Novartis | 1 | $21 |
| Oyster Point Pharma, Inc. | 1 | $21 |
| Sight Sciences, Inc. | 1 | $16 |
| Omeros Corporation | 1 | $14 |
| Aerie Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERACITY SURGICAL$5,589
- enVista MX60 IOL$300
- enVista Aspire IOL$150
- DURYSTA$124
- Oxervate$120
- Clareon$115
- Hydrus$107
- iDose$107
- Rocklatan$105
- Rhopressa$105
How this compares
$7,537 in reported general payments places this provider in the 90th percentile of 80 ophthalmology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 64 | $38,255 |
| RestasisCyclosporine | 25 | $29,381 |
| RhopressaNetarsudil Mesylate | 13 | $11,539 |
| Prednisolone Acetate | 194 | $9,921 |
| Cyclosporine | 23 | $9,381 |
| CombiganBrimonidine Tartrate/Timolol | 12 | $5,432 |
| Ketorolac Tromethamine | 213 | $4,049 |
| Latanoprost | 394 | $3,650 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 130 | $2,565 |
| Timolol Maleate | 176 | $2,064 |
| Ofloxacin | 188 | $1,905 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 21 | $1,646 |
| Fluorometholone | 12 | $1,061 |
| Brimonidine Tartrate | 69 | $854 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $483 | $73,069101 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $13 | $11,53913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 80 ophthalmology providers in New Hampshire.
Other ophthalmology in Peterborough
- Dane SlentzDerry$127K
- Jason SzelogPortsmouth$71K
- Andrew CatomerisLebanon$56K
- Jennifer LingPortsmouth$9K
- John DagianisNashua$9K
- Mohamed GuenenaDerry$8K
- Ahad FazelatManchester$8K
- Gerald SpindelDerry$7K
- Thamolwan SurakiatchanukulLebanon$7K
- Francis LamyLondonderry$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.